<unk><unk><unk>  Syndrome (ARDS) is a form of non-cardiogenic pulmonary edema attributed to the breakdown of alveolar membrane and capillaries leading to hypoxia. The treatment of ARDS has evolved over the last decade. The management of<unk> -19 related ARDS are stratified according to the classification of ARDS. Among patients with<unk> -19, ARDS developed in 20% after a median of eight days after onset of symptoms; mechanical ventilation was implemented in 12.3%. The mortality rate of<unk> -19 related ARDS is higher in elderly patients. Given the importance of heterogeneity in the ARDS profile, appropriate intervention at an appropriate time is needed to help to prevent the deterioration of lung function. Recent advances observed from the RECOVERY trial has further strengthened the notion that the use of dexamethasone in patients on a ventilator can reduce the mortality rate of patients by one-third. The treatment of<unk> -19 related ARDS is evolving with time and different treatment options are now available for the management of ARDS.
COVID-19-associated acute respiratory distress syndrome
COVID-19-associated respiratory failure
COVID-19-associated hemodialysis
COVID-19-associated Guillain-Barre syndrome
COVID-19-associated cytokine storm
COVID-19-associated multisystem inflammatory syndrome
COVID-19-associated pulmonary embolism
COVID-19-associated heart failure